通函及年度股东大会通告 致股东函件 尊敬的各位股东 ： 我们满怀自豪和乐观，与大家分享百济神州在迈向它的宏伟愿景征程中所取得的非凡 成绩。我们致力于成为全球最具影响力的肿瘤治疗创新公司。为此，我们正重新构想 癌症治疗的无限可能——在创新道路上无所畏惧，在全球范围不断扩大药物可及性， 改变未来几代人的生活。 全球已有超过150万例患者接受了我们药物的治疗——这项里程碑再次激发了我们取得更多成绩的热情。我们在全球六 大洲拥有11,000多名员工，团队万众一心，只为实现一个目标 ：为癌症患者带去希望。我们不断突破科学边界，并致力 于让创新的、改变生活的疗法变得更可负担、更可及，且更具影响力——以期惠及全球各地每一位患者。 我们最近庆祝了公司2024年杰出的业绩创下了历史新高 ；2025年，我们的发展将迈上新台阶。今年上半年，我们计划 将启用新英文名称BeOne Medicines Ltd.，并将注册地迁至瑞士，这两项决定展现出我们不断扩大的全球足迹和差异化 的使命担当。 公司英文名称拟变更为BeOne源自于我们工作的重心 ：凝聚全球力量，消除癌症。新的公司品牌标识主要展现出的设计 亮点包括 ： 新英文名称的启用是公 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 | A 股代码：688235 | A 股简称：百济神州 | 公告编号：2025-014 | | --- | --- | --- | | 港股代码：06160 | 港股简称：百济神州 | | | 美股代码：ONC | | | 百济神州有限公司 关于召开 2025 年年度股东大会的通知 （一） 股东大会类型和届次 2025 年年度股东大会 召开日期时间：2025 年 5 月 21 日 21 点 30 分（北京时间） 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 5 月 21 日 股东大会召开日期：2025年5月21日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票、邮寄投票（仅 限非 A 股股东）和网络投票相结合的方式 （四） 现场会议召开的日期、时间和地点 召开地点：Mourant Gov ...

Group 1 - BeiGene announced the termination of the clinical development plan for Ociperlimab, an anti-TIGIT antibody, as a potential treatment for lung cancer based on an independent data monitoring committee's recommendation [1] - The phase 3 clinical trial (AdvanTIG-302) was suggested to be terminated due to the overall efficacy and safety data indicating difficulty in achieving the primary endpoint of overall survival [1] - As of mid-2024, BeiGene has invested a total of 2.09 billion yuan in the Ociperlimab project, which has enrolled over 2,000 patients [1] Group 2 - TIGIT is considered a potential target for tumor immunotherapy following PD-1/PD-L1, with its mechanism involving the blockade of TIGIT-ligand binding to reactivate T cells against tumors [2] - Roche has been a leader in the TIGIT target field, but announced the termination of several clinical trials related to TIGIT antibodies due to unmet expectations in lung cancer trials [2] - Merck also announced the termination of its TIGIT monoclonal antibody Vibostolimab's clinical development project after its phase 3 trial faced failure [2]

"数"说科创板 2025年3月 总体情况 截至2025年3月底，科创板上市公司共计586家。其中，集成电路领域公司总数 达119家，占A股同类上市公司的"半壁江山"，涵盖上游芯片设计、中游晶圆代工及 下游封装测试，形成上下游链条完整、产业功能齐备的发展格局；生物医药领域上 市公司总数112家，重点介入癌症、艾滋病、乙肝、丙肝等治疗领域，已成为美国、 香港之外全球主要上市地；新能源领域，已有17家光伏企业，20家动力电池产业链 公司，绿色经济发展势头良好；工业机器人、轨道交通等产业链也已初具规模。 01 地区分布情况 截至3月底，科创板上市公司已覆盖全国23省（自治区、直辖市），家数排名前五的省市为江苏 省113家，上海93家，广东省91家，北京76家，浙江省51家，合计424家，占比72%。长三角三省一市 合计281家，占比48%。 02 募集资金情况 科创板586家公司合计首发募集资金总额9,207.82亿元。科创板公司平均募集资金金额为15.74亿 元，最大值为中芯国际532.3亿元，中位数为9.90亿元。 科创板公司募集资金前五名 科创板公司募集资金分布情况 | 证券代码 | 证券简称 | 募资总额 | ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of BeiGene, a global biotechnology company focused on innovative drug development and commercialization [1][2] - As of April 1, BeiGene's stock closed at 249.51 yuan, reflecting a 4.47% increase, with a market capitalization of 349.402 billion yuan and a price-to-book ratio of 14.45 [1] - The latest quarterly report for Q3 2024 shows BeiGene achieved a revenue of 19.136 billion yuan, representing a year-on-year increase of 48.63%, while the net profit was -3.686694 million yuan, a year-on-year decrease of 4.94%, with a gross margin of 83.94% [1] Group 2 - The shareholder structure indicates that as of September 30, 2024, BeiGene had 33,458 shareholders, a decrease of 4,146 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - In comparison to industry peers, BeiGene's price-to-earnings ratio (TTM) is -70.19, while the industry average is 42.46, indicating a significant divergence in valuation metrics [2] - The industry median price-to-earnings ratio is 37.51, further illustrating the relative valuation challenges faced by BeiGene compared to its competitors [2]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年4月1日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份 ...

呈交日期： 2025年3月31日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | ...

Policy Developments - Ningxia is implementing a dual-track "monthly prepayment + annual prepayment" mechanism for medical insurance funds, aiming for real-time settlement with medical institutions by 2025. In the first two months of 2025, 255 million yuan was prepaid to designated medical institutions under the annual prepayment model [2] - The Ministry of Commerce will collaborate with the National Health Commission to release the "Health Consumption Special Action Plan" during the China International Consumer Products Expo, focusing on health-related sectors such as diet, fitness, and elderly care [3] Drug Approvals - The NMPA approved the launch of the novel antiviral drug Marzula Shave, developed by Qingfeng Pharmaceutical, for treating uncomplicated influenza in adolescents and adults aged 12 and above [6] - Merck's 21-valent pneumococcal conjugate vaccine Capvaxive has been approved for marketing in the EU, targeting invasive pneumococcal disease and pneumonia in adults [7][8] Capital Market Activities - Shanghai Laishi plans to acquire 100% of Nanyue Biological for 4.2 billion yuan to expand its plasma resources and production capabilities [10] - Lizhu Pharmaceutical intends to invest 1 billion yuan in Lizhu Biopharmaceutical to support its R&D projects and operational needs, valuing Lizhu Biopharmaceutical at 11.8 billion yuan [11] Industry Developments - Bayer signed a global licensing agreement with Suzhou Puhua Pharmaceutical for a PRMT5 inhibitor targeting MTAP-deficient tumors, with the first patient enrolled in a Phase I clinical trial [13] - Huadong Medicine's dual-target antibody drug HDM3019 has received clinical approval in China, with a collaboration agreement worth over 300 million USD for the development of autoimmune disease treatments [14] Financial Reports - iFlytek Medical Technology reported a revenue of 734 million yuan for 2024, a 32% increase from 2023, but still faced a net loss of 133 million yuan [19] - Yonghe Medical's revenue grew by 1.5% to 1.8045 billion yuan, with a reduced net loss of 226.6 million yuan [20] - BeiGene's revenue for 2024 reached approximately 3.8 billion USD, a 55% increase, with product revenue rising by 72.6% [21] - Shanghai Pharmaceuticals achieved a revenue of 275.251 billion yuan in 2024, a 5.75% year-on-year growth, with a net profit of 4.553 billion yuan [22] - Innovent Biologics reported a revenue of 1 billion yuan from its drug Abobotinib, driven by its inclusion in medical insurance [23] - Rhine Biotech's revenue for 2024 was 1.772 billion yuan, with a net profit of 163 million yuan, marking a 97.56% increase [24] - Rongchang Biotech reported a revenue of 1.717 billion yuan for 2024, with a net loss of 1.468 billion yuan [25]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 截至2024年12月31日止年度 全年業績公告 百濟神州有限公司連同其子公司（「本公司」或「百濟神州」或「我們」）謹此公佈本 公司截至2024年12月31日止年度（「報告期」）的綜合業績連同2023年相應期間的 比較數字，其乃根據美國公認會計原則（「美國公認會計原則」或「GAAP」）編製並 由本公司董事會（「董事會」）審計委員會（「審計委員會」）審閱。 財務摘要 1 • 截至2024年12月31日止年度的收入合計較截至2023年12月31日止年度增加 約14億美元或約55.0%至約38億美元。產品收入較截至2023年12月31日止 年度增加約16億美元或約72.6%至約38億美元。 • 截至2024年12月31日止年度的經營費用合計較截至2023年12月31日止年度 增加約497.8百萬美元或約15. ...

Core Insights - Company reported a revenue increase of approximately $1.4 billion or about 55.0% to around $3.8 billion for the fiscal year ending December 31, 2024 [1] - Product revenue rose by approximately $1.6 billion or about 72.6% compared to the previous year [1] - Net loss for the fiscal year ending December 31, 2024, decreased by approximately $236.9 million or about 26.9% to around $644.8 million [1] Financial Performance - Adjusted gross margin for product sales improved, with cash and cash equivalents reaching $2.6 billion as of December 31, 2024 [1] - Since 2023, the current product portfolio and core product revenue have grown by 73%, with expectations for significant growth in product revenue in 2025 and beyond [1] - Research and development expenses increased by $174.7 million or 9.8% to $2 billion for the fiscal year ending December 31, 2024 [1] Market Position - The company's strong annual performance highlights its position as a global leader in cancer treatment, driven by the ongoing success of its flagship product and a robust pipeline in oncology [1] - Multiple projects are expected to advance in 2025, indicating a promising outlook for the company's future growth in the oncology sector [1]